Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase EARLY_PHASE1 1

Status

Recruiting 2Completed 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Pancreatic Neoplasms 2Neoplasm Metastasis 2High Risk Myeloid Malignancies 1

Interventions

pembrolizumab 79Cyclophosphamide 55Specimen Handling 54Carboplatin 50fludarabine 44Nivolumab 42Magnetic Resonance Spectroscopy 42Biopsy 38Gemcitabine 37Bevacizumab 34Dexamethasone 31venetoclax 27Paclitaxel 26Injections 25Docetaxel 25atezolizumab 24Pemetrexed 24Cisplatin 24Ipilimumab 23Capecitabine 21Temozolomide 19Fulvestrant 19abemaciclib 18Rituximab 18Oxaliplatin 18Lenalidomide 18Cetuximab 18Azacitidine 18Vincristine 15Fluorouracil 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Transplantation Conditioning × 90 days × Clear all
NCT07627711 2026-06-04

DUAL-NK-PDAC

Beijing Biotech

Phase 1/2 Recruiting
42 enrolled
Gastrointestinal

Neoplasm Metastasis, Pancreatic Neoplasms

NCT04990323 2026-03-24

US Study of ECT-001-CB in Pediatric and Young Adult Patients With High-Risk Myeloid Malignancies

ExCellThera inc.

Phase 1/2 Completed
13 enrolled

High Risk Myeloid Malignancies

NCT07480928 2026-03-18

DUAL-NK-PDAC

Beijing Biotech

Phase 1/2 Recruiting
42 enrolled
Gastrointestinal

Neoplasm Metastasis, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡